SUBSCRIBE
SUBSCRIBE
News   Drug Development

Array BioPharma, Inc. Initiates Phase 1 Clinical Trial for MEK Inhibitor ARRY-300

January 9, 2009 | 
1 min read

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) has initiated dosing in healthy volunteers in a Phase 1 clinical trial with ARRY-300, a targeted small molecule MEK inhibitor.

Clinical research Phase I
MORE ON THIS TOPIC
Pictured: Sarepta sign on a brick building/courtes
Gene Therapy
Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies
March 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern collage with halftone hands give and take money. Financial transaction. Money investments. Cash payment. Pay for something
GLP-1
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic
March 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern halftone collage. Concept of teamwork, problem solving together, business direction, collaborate to win,achieve success. Business creative illustration for web banner, marketing material, business presentation. Vector illustration
GLP-1
Altimmune Jumps On Takeover Rumors After Launching Alcohol Use Disorder Study
March 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Take a chance for keeping advance
Duchenne muscular dystrophy
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
March 17, 2025
 · 
2 min read
 · 
Tristan Manalac